Onco404

03/07/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
---
Kansere karşı mücadelede kendimizi bilgiyle güçlendirmek için temel terimleri açıklarken bize katılın.

27/06/2025

27/06/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
---
Kansere karşı mücadelede kendimizi bilgiyle güçlendirmek için temel terimleri açıklarken bize katılın.

30/05/2025

The TuPro study used 9 multi-omics technologies (scRNA-seq, proteomics, pharmacoscopy, etc.) to profile 116 melanoma patients, generating >40,000 markers/sample in just 4 weeks.

Nature Medicine

📊 Key Findings
✅ In 75% of cases, TuPro-based data (beyond standard NGS) was judged useful by the molecular tumor board for treatment recommendations. 54 distinct markers informed decisions.
☑️ Beyond SOC patients (n=37) achieved 38% objective response rate (ORR) and 54% disease control rate (DCR) - remarkable for refractory cases!
✅ PFS: 6.04 months (overall palliative), 5.35 months (≥3rd-line therapy).
☑️ Outperformed non-TuPro matched cohorts: 64.7% DCR (TuPro) vs. 23.5% (non-TuPro) in ≥3rd-line patients.
✅ Cost-effective: 1.8x higher than standard NGS but enabled highly individualized therapies.

Multi-omics profiling is feasible, accelerates precision oncology, and improves outcomes for advanced melanoma.

29/05/2025

This integrated analysis of CodeBreaK 100 & 200 trials delves into biomarkers influencing sotorasib efficacy in KRAS G12C-mutated NSCLC.

Nature Medicine

📊 Key Findings
☑️ KEAP1 co-mutations were correlated with significantly shorter PFS and OS on sotorasib.
✅ NRF2 activation (often linked to KEAP1 mutations) was also associated with inferior outcomes: mPFS: 2.73 vs 7.75 months (NRF2 low)
☑️ TTF-1 low tumors showed poor outcomes. ORR: 4.17% vs 42.1% (TTF-1 high); mPFS: 2.76 vs 8.11 months (HR 0.23); mOS: 4.47 vs 16 months.
✅ Integration of NRF2 activation status and TTF-1 expression enabled robust partitioning of patients into favorable (~70%), intermediate (~13%) and poor (~17%) prognostic groups.
☑️ KRAS G12C ctDNA negativity at C1D8 → mPFS 7.26 vs 4.01 months
✅ ATM mutations reduced sotorasib benefit vs docetaxel (mPFS: 4.17 vs 8.25 months).

💡 These biomarkers enable precision patient selection and identify candidates for combination therapies. TTF-1 IHC (clinically feasible) may guide frontline decisions.

28/05/2025

A cluster randomized trial tested if algorithm-based EHR defaults with accountable justification could increase specialty palliative care (PC) consultations.

JAMA Oncology

📊 Key Findings
✅ 43.9% (intervention) vs. 8.3% (control) completed PC consults (adjusted OR: 8.9) ⤴️
☑️ Systemic therapy within 14 days of death was lower in the intervention group (6.5%) compared to control (16.1%; AOR 0.3).
❌ No significant differences in quality of life, feeling "heard/understood," or late hospice referrals.
✅ This scalable EHR-based strategy addressed clinician barriers (only 10.5% opted out of defaults), increased PC access without overburdening workflows, and offers a pragmatic solution for resource-limited settings.

28/05/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.
---
Kansere karşı mücadelede kendimizi bilgiyle güçlendirmek için temel terimleri açıklarken bize katılın.

27/05/2025

A new study analyzed 233 trials associated with 207 FDA approvals (2015–2020) and found alarming gaps in health-related quality of life (HRQoL) reporting.

BMJ

📊 Key Findings
📉 50% of trials reported HRQoL data, but only 42% had it available by FDA approval.
📉 79% of approvals relied on surrogate endpoints (e.g., PFS), yet only 18% of these showed improved HRQoL.
💊 Trials with survival (OS) endpoints: 70% reported HRQoL vs. 45% for surrogate endpoints.
📊 HRQoL improved in 43% of trials overall but worsened in 4%, all linked to surrogate-based approvals.
⚠️ Reporting hasn’t improved since 2015. Delays mean doctors and patients often wait 6+ months for critical QoL data, long after drugs hit the market.
⚠️ Median latency for HRQoL reporting was 1.1 months post-approval, but a quarter took over a year.

Timely and comprehensive HRQoL data is vital for integrating patient experiences into clinical and regulatory decision-making.